Peripheral Neuropathy

Download as ppt, pdf, or txt
Download as ppt, pdf, or txt
You are on page 1of 49

Peripheral Neuropathy

Department of Neurology,
General hospital
Ningxia Medical University
Haining Li
Peripheral Neuropathy
 Outline
 Guillain-Barre Syndrome
 Idiopathic facial palsy
 Trigeminal neuralgia
OUTLINE
 Anatomy
 Pathological Processes
 Clinical classifation
 Symptoms
 Investigation
Anatomy
Peripheral nerves are made up of numerous axons
bound together by three types of connective
tissue—endoneurium, perineurium, epineurium.
Peripheral nerve trunks contain myelinated and
unmyelinated fibres.
 Crinial nerves
 Spinal nerves
Pathological Processes
 Wallerian degeneration: disintegration of
axons and myelin distal to the site of injury.
 Axonal degeneration: distal dying of axons
and loss of myelin.
 Neuronal degeneration: death of neuron body
 Segmental demyelination
Normal Wallerian Axonal Neuronal Segmental
degeneration degeneration degeneration demyelination
Symptoms
 Sensory disturbance
 Motor deficits
 Tendon reflexes
 Autonomic disturbances
 Others
Investigation
 Nerve conduction velocity(NCV)
 Electromyography(EMG)
 Nerve biopsy
 Blood tests
 CSF examination
Trigeminal Neuralgia
Etiology and Pathology
 A facial pain syndrome of unknown cause.
 Demyelination
Clinical Features
 It develops in middle to late life.
 It consists of severe paroxysms electric-
shock-like pain, usually in the V3 and V2
division of the trigeminal nerve, lasting for
several seconds or minutes each time.
 Involvement of V1 division or bilateral
disease occurs in less than 5% of cases.
Clinical Features
 Occurrence during sleep is rare.
 Painfree intervals may last for minutes to
weeks, but long-term spontaneous remission is
rare.
 Sensory stimulation of trigger zones about the
cheek, nose, or mouth by touch, cold, wind,
talking, or chewing can precipitate the pain.
Clinical Features

 Course could be periodic


 Physical examination is normal
Diagnosis and Differential Diagnosis
 Diagnosis
depending on the clinical features
 Differential Diagnosis
 Secondary trigeminal neuralgia
 Tooth ache
 Glosspharyngeal neuralgia
Treatment
 Drug is preferential
AEDs: carbamazapine 0.1 bid po
phenitoin, clonazepam
 Baclofen
 VitaminB12
 Surgery
Idiopathic Facial Palsy
(Bell’s palsy)
Idiopathic Facial Palsy
(Bell’s palsy)
 Anatomy
 Etiology and pathogenesis
 Clinical features
 Diagnosis and differential diagnosis
 Treatment
Etiology and Pathology

 Etiology: unknown
 Pathology: edema, demyelination, axonal
degeneration
Clinical features

 Onset
□ Occurs in any age, usually unilateral.
□ Paralysis: Progresses over 3 to 72 hours
□ Pain (50%): Near mastoid process
□ Excess tearing (33%)
□ Other: Hyperacusis; Dysgeusia
Clinical features
 Signs
□ Facial weakness
Upper & Lower
Unilateral
Degree: Partial (30%); Complete (70%)
□ Stapedius dysfunction (33%): Hyperacusis
□ Lacrimation: mildly affected in some patients
□ Taste: No clinically significant changes in most
patients.
□ There should be no sensory loss in the face.
□ No abnormalities beyond the territory of the facial
nerve.
□ Hunt syndrome: caused by reactivation of herpes zoster
in the geniculate ganglion, consists of a severe facial palsy
associated with a vesicular eruption in the external
auditory canal and sometimes in the pharynx and other
parts of the cranial integument; often the eighth cranial
nerve is affected as well.
Clinical features
 Prognosis better
□ Incomplete paralysis

□ Early improvement

□ Slow progression

□ Younger age
Clinical features

 Prognosis better
□ Normal taste
□ Electrodiagnostic tests normal
Diagnosis and differential diagnosis
 Diagnosis: acute onset with peripheral facial
palsy.
 Differential diagnosis:
 GBS
Treatment
 Corticosteroids: prednisone 60mg qd po
dexamethason
 VitaminB1,B12
 Baclofen
 Rehabilitation
 Physiotherapy
Guillain-barré Syndrome
GBS is a kind of autoimmune disease
characterized by demyelination of peripheral
nerves and nerve roots. Inflammation of
lymphocytes and macrophages around small
vessels is the pathological feature.
Clinical classification
 AIDP
 AMAN
 AMSAN
 Fisher syndrome ( gait ataxia, areflexia,
and external ophthalmoplegia)
 Unclassifiable GBS
Epidemiology

 Incidence: 0.6 to 1.9/100,000/year


 Male: Female = 1.25: 1
 Peak ages: 16~25 years old
45~60 years old
Etiology and pathogenesis
 The precise cause is unclear.
 GBS often follows minor infective illness,
inoculations or surgical procedures.
Clinical and epidemiologic evidence
suggest an association with preceding
Campylobacter Jejuni(CJ) infection.
 The pathogenesis resembles EAN
Molecular mimicry
Clinical features
 GBS Prodrome
It often follows 1-4 weeks after a respiratory
infection or diarrhea.
Campylobacter jejuni(CJ) has been particularly
implicated as a cause of the diarrhea.
Clinical features

 Weakness: Most often symptomatic in legs


Distribution: Proximal + Distal; Symmetric
Severity: Quadriplegia in 30%;
Bedbound another 30%
Respiratory failure.
Clinical features
 Sensory: ususlly less marked than motor
symptoms.
Paraesthesias: Initial symptom in 50%;
Eventually occur in 70% to 90%
Pain
Loss: with classic glove-and-stocking pattern
of sensory loss, but rarely occurs.
Clinical features

 Cranial nerve: Ⅶ, Ⅸ,Ⅹ


facial weakness is present in 50% of cases.
 Autonomic dysfunction
tachycardia, cardiac irregularitis, labile blood
presure, disturbed sweating and so on.
 Monophase course
Investigations
 CSF: a characteristic abnormality, with increased
protein concentration but a normal cell count.
 Eletrophysiologic studies
 marked slowing of motor and sensory condu-
ction velocity,
 evidence of denervation and axonal loss.
 F wave reflex is delayed or absent.
 Sural nerve biopsy: demyelination
Diagnostic criteria for GBS(1)

Acute or subacute progressive weakness of


more than one limb.
Distal areflexia with proximal areflexia
or hyporeflexia.
Progression for up to 4 weaks.
Relatively symmetric deficits.
Mild sensory involvement.
Diagnostic criteria for GBS(2)
Cranial nerve(especiallyⅦ)involvement.
Recovery beginning within 4 weeks after
progression stops.
Autonomic dysfunction.
Increased CSF protein after 1 week.
CSF white blood cell count10/l.
Nerve conduction slowing and F wave reflex
delayed or absent.
Treatment
 Assisting respiration: Patients who are seve -
rely affected are best managed in ICU where
facilities are available for monitoring and assis-
ted respiration if necessary. Sometimes
antibiotic is necessary for preventing
respiratory tract’s infection.
FVC<15ml/kg, PO2<70mmHg
 Symptomatic therapy: The aim is to prevent
such complications as respiratory failure or
vascular collapse.
Treatment
 Etiological therapy:
Plasma exchange ( plasmapheresis)
Intravenous immunoglobulin:
0.4g /kg /d for 5 days
Corticosteroids: it has not been successful
in acute GBS and can bring about adverse
outcome.
 Rehabilitation
Prognosis
 The disorder is self-limiting,and improvement
occurs over the weeks or months following
onset. About 70-75% of patients recover
completely, 25% are left with mild neurologic
deficits, and 5% die, usually as a result of
respiratory failure.
 The prognosis is poorer when there is
evidence of preceding CJ infection.
Chronic inflammatory
demyelinating polyneuropathy
(CIDP)
Epidemiology
 Occurs at any age, peak time is 40-60 years old
adults.
Clinical Manifestations

Chronic, relapsing inflammatory


polyradiculoneuropathy.
Weakness and areflexia are characteristic signs.
Course is more than 2 months.
Treatment
 Steroids
 IVIg
Thank you

You might also like